Literature DB >> 82034

Pathogenesis of prolactin-secreting pituitary adenomas.

B M Sherman, C E Harris, J Schlechte, T M Duello, N S Halmi, J VanGilder, F K Chapler, D K Granner.   

Abstract

42 women with amenorrhoea and hyperprolactinaemia had trans-sphenoidal surgery and resection of histologically verified pituitary adenomas. 74% of these patients developed amenorrhoea and/or galactorrhoea in immediate association with the use or discontinuation of oral contraceptives or post partum. There was enough adenomatous tissue for immunocytochemical studies in 35 specimens and specific localisation of prolactin was possible in 31. There is evidence that about 10% of the population have small pituitary tumours, and the majority of these tumours, though asymptomatic, are potentially prolactin-secreting. It is suggested that oestrogens, which are known to modulate prolactin secretion in normal human beings and in animals, can induce the growth and expression of otherwise silent pituitary lesions and that this should be considered a risk of oral-contraceptive use.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 82034     DOI: 10.1016/s0140-6736(78)92339-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

1.  Effect of estrogens on prolactin secretion in transsexual subjects.

Authors:  H H Goh; S S Ratnam
Journal:  Arch Sex Behav       Date:  1990-10

Review 2.  Genesis of prolactinomas: studies using estrogen-treated animals.

Authors:  Dipak K Sarkar
Journal:  Front Horm Res       Date:  2006       Impact factor: 2.606

3.  Effect of long term hormone replacement on plasma prolactin concentrations in women after oophorectomy.

Authors:  D H Barlow; G H Beastall; H I Abdalla; J Elias-Jones; R Lindsay; D M Hart
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-23

4.  Prolactinoma in a man following industrial exposure to estrogens.

Authors:  S H Baron; J R Sowers; M Feinberg
Journal:  West J Med       Date:  1983-05

5.  Oral contraceptives and pituitary adenomas.

Authors:  S J Wingrave; C R Kay; M P Vessey
Journal:  Br Med J       Date:  1980-03-08

6.  The management of prolactin-secreting pituitary tumors.

Authors:  S R George; G N Burrow
Journal:  J Endocrinol Invest       Date:  1981 Oct-Dec       Impact factor: 4.256

7.  Galactorrhoea, hyperprolactinaemia, and pituitary adenoma presenting during metoclopramide therapy.

Authors:  B T Cooper; R A Mountford; C McKee
Journal:  Postgrad Med J       Date:  1982-05       Impact factor: 2.401

8.  Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy.

Authors:  M M Garcia; L P Kapcala
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

9.  Beta-adrenoceptor-blocking drugs, growth hormone and acromegaly.

Authors:  J Feely
Journal:  Postgrad Med J       Date:  1980-04       Impact factor: 2.401

Review 10.  Potential of gene therapy for the treatment of pituitary tumors.

Authors:  R G Goya; D K Sarkar; O A Brown; C B Hereñú
Journal:  Curr Gene Ther       Date:  2004-03       Impact factor: 4.391

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.